Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

The de-extinct dire wolves created by a biotechnology company are now old enough to breed, according to the firm behind the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...

A weekly newsletter focusing on the most important news in health and biotech. Founded at the Massachusetts Institute of ...

Explore advancements in biotechnology, from gene editing's ethical dilemmas to synthetic biology's commercial potential and ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...